Pyrimidine Compounds Inhibiting TPH1 for Peripheral Serotonin Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders related to serotonin often come with adverse effects due to direct manipulation of serotonin receptors, highlighting a need for alternative methods that specifically target peripheral serotonin levels without affecting central nervous system serotonin.
Innovation Solution
Development of 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds that inhibit tryptophan hydroxylase (TPH), particularly TPH1, to reduce peripheral serotonin levels while minimizing impact on central nervous system serotonin levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs directly manipulate serotonin receptors, then therapeutic effect on serotonin-related diseases is achieved, but adverse effects occur due to broad impact on serotonin pathways
Solution Approach 1:
The patent segments the serotonin system into two distinct targets: peripheral TPH1 enzyme and central TPH2 enzyme. By designing compounds that selectively inhibit TPH1 while sparing TPH2, the invention divides the therapeutic action to affect only peripheral serotonin synthesis, thereby achieving treatment of peripheral serotonin-related disorders without disrupting central serotonin pathways that mediate mood and behavior.
Solution Approach 2:
The invention applies local quality by creating compounds with differential affinity for TPH1 versus TPH2 isoforms. The molecular structure is optimized to interact specifically with the peripheral TPH1 enzyme's active site while having reduced affinity for central TPH2, thereby localizing the pharmacological effect to peripheral tissues and avoiding central nervous system side effects.
2Reliability
If peripheral serotonin levels are reduced to treat peripheral disorders, then therapeutic benefit is achieved, but risk of affecting central nervous system serotonin increases
Solution Approach 1:
The patent uses the peripheral TPH1 enzyme as an intermediary target rather than directly affecting serotonin receptors in the CNS. By inhibiting TPH1, the compound indirectly reduces peripheral serotonin levels without needing to cross the blood-brain barrier or directly interact with central serotonin receptors, thereby decoupling peripheral therapeutic effects from central side effects.
Solution Approach 2:
The invention extracts the peripheral serotonin synthesis pathway from the central serotonin system by selectively targeting TPH1. This allows independent modulation of peripheral serotonin levels while leaving central serotonin homeostasis intact, effectively separating the two previously interconnected systems for therapeutic purposes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat, prevent, and manage diseases and disorders mediated by peripheral serotonin with a broad safety margin, reducing the risk of adverse effects on the central nervous system.
Implementation Method 1
Particular compounds inhibit TPH (e.g., TPH1) activity
Data Source
AI summary
Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders.